[go: up one dir, main page]

US20100120904A1 - Novel use of genistein - Google Patents

Novel use of genistein Download PDF

Info

Publication number
US20100120904A1
US20100120904A1 US12/594,284 US59428408A US2010120904A1 US 20100120904 A1 US20100120904 A1 US 20100120904A1 US 59428408 A US59428408 A US 59428408A US 2010120904 A1 US2010120904 A1 US 2010120904A1
Authority
US
United States
Prior art keywords
genistein
composition
dry eye
treatment
lkc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/594,284
Other languages
English (en)
Inventor
Kevin Prudence
Christoph Riegger
Wolfgang Schalch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Assigned to DSM IP ASSESTS B.V. reassignment DSM IP ASSESTS B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PRUDENCE, KEVIN, RIEGGER, CHRISTOPH, SCHALCH, WOLFGANG
Publication of US20100120904A1 publication Critical patent/US20100120904A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to a novel use of genistein and to compositions comprising it. More precisely, the present invention relates to the use of genistein and compositions containing it in the treatment and prevention of dry eye syndrome and to compositions containing it.
  • Dry eye was defined by the National Eye Institute (NEI)/Industry Workshop in 1993 as a “disorder” of the tear film due to tear deficiency or excessive evaporation, which causes damage to the interpalpebral ocular surface and is associated with symptoms of discomfort (Lemp, M. A.: CLAO J. 1995, 21: 221-232). Based on current knowledge of dry eye, it is also appropriate to consider it as an ocular surface inflammatory syndrome rather than simply a tear insufficiency.
  • KCS keratoconjunctivitis sicca
  • LSC lacrimal keratoconjunctivitis
  • HRT hormone replacement treatment
  • genistein a compound naturally occurring in plants and known to have estrogenic activity, can be used in the treatment of LKC.
  • the possibility of using genistein has not yet been proposed, although the idea of estrogens and androgens as a systemic treatment has been discussed (Scott, G. et al., Am. J. Ophthalmol. 39, 1109-10, 2005).
  • Genistein receptors have been found in the thymus, causing them to be effective in immune system regulation (Cooke, P. S., et al.; J. Nutr. 136, 704-8, 2006). Genistein has also been noted to affect the androgen/estrogen-induced signaling pathways via gene response modulation (Takahashi, Y., et al., Mol. Carcinog. 45, 18-25, 2006) and genistein has been found to have specific ocular activity by virtue of its inhibitory effects of ocular neovascularization (Kruse, F. E., et al., Ophthalmology 94, 152-6, 1997).
  • the demonstrated activity of the phyto-estrogen genistein as a modulatory agent of both the immune system and androgen-estrogen signaling, together with its parallel activity against neovascularization, as well as the presence of sex steroid receptors in the ocular surface are demonstrative of the surprising and previously unreported activity of genistein in the treatment and prevention of dry eyes.
  • the present invention therefore, relates to the use of genistein in the treatment and prevention of dry eye syndrome or of LKC or in the manufacture of compositions useful in the treatment and prevention of dry eye syndrome or of LKC in a human or animal; to a method of treatment and prevention of dry eye syndrome or of LKC in humans or animals and to corresponding compositions, preferably for oral application, containing an effective amount of genistein.
  • the term “genistein” in the context of the present invention relates to 4′,5,7-trihydroxy-isoflavone and comprises this compound in all forms, i.e., in free form or as salts, and from all sources, i.e. irrespective of whether it is prepared synthetically, by genetic engineering and expression from microorganisms or isolated from natural sources and in more or less concentrated and purified form.
  • the term “genistein” in the context of the present invention also relates to biologically equivalent derivatives of genistein, i.e., compounds derived from genistein, occurring in nature, i.e.
  • genistein in natural sources or as metabolites in metabolic pathways, such as glycosides, e.g., genistin, or as glucuronides, or compounds obtainable from genistein by chemical modification or synthesis. All derivatives are included which are biologically equivalent to genistein, which means that in the organism to which they are applied they are transformed into the pharmacologically active form of genistein.
  • compositions and application forms of the present invention are those which are generally known in the art and already used for the treatment and prevention of other medical indications and diseases.
  • Such compositions comprise preparations for systemic, e.g., oral or parenteral but also for local and topical applications in the form of pharmaceutical as well as nutraceutical preparations, such as tablets, capsules, eye drops, ointments, gels, patches or sprays and other galenical dosage forms; solutions, concentrates and premixes for food or feed supplementation, and all kinds of food or feed themselves, including beverages.
  • mammals comprises all animals which may suffer from dry eye syndrome or LKC, especially mammals, preferably farm animals, such as ruminants, horses and pigs; pets, such as cats and dogs, and animals kept in zoological gardens.
  • Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art.
  • a typical range of daily administration is from about 1 to about 500 mg, preferably from about 5 to about 100 mg, if administered systemically.
  • Topical, especially ocular administration e.g., in the form of eye drops, eye emulsions and eye sprays, typically will involve the administration of from about 0.1 mg total to about 5 mg total, preferably 0.5-1 mg total, of genistein.
  • Typical solutions for topical use contain genistein in a concentration of 0.0025-5%, preferably at least 0.01% and preferably up to 1%, more preferably up to 0.5%, most preferably up to 0.05%, w/v.
  • a preferred concentration is 100 ⁇ M.
  • genistein derivatives these values have to be adapted corresponding to their bioavailabilities compared with the bioavailability of genistein itself. More details on suitable formulations in case of pharmaceutical compositions of genistein in its present new use are available from existing literature, e.g., WO 99/45920 or WO 98/26784.
  • compositions containing genistein can be prepared by procedures known in the art.
  • genistein can be formulated into tablets, capsules, powders, suspensions, solutions for parenteral and topical administration including intravenous, intramuscular, and subcutaneous administration, and into solutions for application onto patches for transdermal application with common and conventional carriers, binders, diluents, and excipients.
  • a pharmaceutical formulation for use in the methods of the present invention includes a genistein which is at least 40% pure, preferably at least 85% pure.
  • Inert pharmaceutically acceptable carriers useful to form pharmaceutical formulations include starch, mannitol, calcium sulfate, dicalcium phosphate, magnesium stearate, silicic derivatives, and/or sugars such as sucrose, lactose, and glucose.
  • Binding agents include carboxymethyl cellulose and other cellulose derivatives, gelatin, natural and synthetic gums including alginates such as sodium alginate, polytheylene glycol, waxes and the like.
  • Diluents useful in the invention include a suitable oil, saline, sugar solutions such as aqueous dextrose or aqueous glucose, and glycols such as polyethylene or polypropylene glycol.
  • excipients include lubricants such as sodium oleate, sodium acetate, sodium stearate, sodium chloride, sodium benzoate, talc, magnesium stearate, and the like; disintegrating agents including agar, calcium carbonate, sodium bicarbonate, starch, xanthan gum, and the like; and adsorptive carriers such as bentonite and kaolin. Coloring and flavoring agents may also be added to the pharmaceutical formulations.
  • a dietary composition in accordance with the method of the present invention is a food or feed ingredient or a food or feed containing genistein and can be prepared by adding genistein to a food or a food ingredient in the process of preparing a food, independent of the source from which the genistein is derived.
  • the foods and feeds to which genistein compounds may be added include almost all foods and feeds including beverages and drinking water.
  • the genistein can be added to foods including, but not limited to, meats such as ground meats, emulsified meats, marinated meats, dried meats and sausages; functional foods; beverages such as nutritional beverages, sports beverages, protein fortified beverages, lemonades, juices, mineral waters, dairy products, milk, milk alternatives, and weight loss or energizing beverages; cheeses such as hard and soft cheeses, cream cheese, and cottage cheese; frozen desserts such as ice cream, ice milk, low fat frozen desserts, and non-dairy frozen desserts; yogurts; soups; puddings; bakery products; cakes and cookies; salad dressings; dips and spreads such as mayonnaise and chip dips; and extruded snack products.
  • meats such as ground meats, emulsified meats, marinated meats, dried meats and sausages
  • functional foods such as nutritional beverages, sports beverages, protein fortified beverages, lemonades, juices, mineral waters, dairy products, milk, milk alternatives, and weight loss or energ
  • genistein is added to the food in an amount selected to deliver a desired dose of it to the consumer of the food.
  • a genistein composition to be added to a food for use as a dietary composition in accordance with the methods of the present invention contains at least 40% genistein preferably at least 85% genistein.
  • Ovarectomized (OVX) female Sprague-Dawley rats 120-160 g are a model for the condition of human menopause (Pflugfelder, S.C. et al. Dry eye and ocular surface disorders. Marcel Dekker, New York, 2004) and, therefore, serve as a natural model of dry eye surface disease.
  • OVX animals may be treated with subcutaneous estradiol in order to compare the effect of this hormone replacement to treatment with genistein.
  • Scopolamine model Another well-accepted model of dry eye is the scopolamine model which utilizes subcutaneous injections (5 mg in 10 ml) or dermal patch or gel dosage (Durson et al., Invest. Ophthalmol. Vis. Sci. 43: 632-8, 2002) of scopolamine to induce a dry eye condition in rats by parasympatholytic blockade of natural tear production.
  • Test animal groups were populated with equal numbers of animals (rats) as follows:
  • Fluorescein was used to observe any local corneal epithelial cell loss, visible as punctuate staining as well as any breakdown in epithelial integrity as evidenced by interstitial staining. Fluorescein was also used to measure the length of time to the break-up (Tear Break Up Time—TBUT) of the tear film, which is a measure of evaporation. The normal range of TBUT is 10 seconds, but comparison of experimental vs. control animals was the primary outcome comparison.
  • Rose Bengal is an organic lipid dye which stains a native cell membrane and is, therefore, used to detect corneal epithelial cells that have an inadequate wetting process.
  • the outcome measure for rose Bengal staining was any positive staining especially in comparison to control animal examinations.
  • FIG. 1 demonstrates the effects of genistein supplementation on tear production in rats treated with scopolamine, an established animal model to study the Dry Eye Syndrome. Tear volume was monitored by the Zone Quick test. This in-life test is a standardized measure of tear production. It consists of a thread impregnated with phenol red which causes a colour change of the length of the thread that becomes wet from tears when the thread is applied to the lacrimal lake. The length (in mm) of the wetted thread is proportional to the tear volume produced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US12/594,284 2007-04-02 2008-04-01 Novel use of genistein Abandoned US20100120904A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07006833.3 2007-04-02
EP07006833 2007-04-02
PCT/EP2008/002563 WO2008119544A1 (en) 2007-04-02 2008-04-01 Novel use of genistein

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/002563 A-371-Of-International WO2008119544A1 (en) 2007-04-02 2008-04-01 Novel use of genistein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/864,974 Continuation US10471041B2 (en) 2007-04-02 2018-01-08 Use of geninstein

Publications (1)

Publication Number Publication Date
US20100120904A1 true US20100120904A1 (en) 2010-05-13

Family

ID=39619083

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/594,284 Abandoned US20100120904A1 (en) 2007-04-02 2008-04-01 Novel use of genistein
US15/864,974 Expired - Fee Related US10471041B2 (en) 2007-04-02 2018-01-08 Use of geninstein

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/864,974 Expired - Fee Related US10471041B2 (en) 2007-04-02 2018-01-08 Use of geninstein

Country Status (8)

Country Link
US (2) US20100120904A1 (pl)
EP (1) EP2129373B1 (pl)
JP (1) JP5327816B2 (pl)
KR (1) KR101472609B1 (pl)
CN (1) CN101652135B (pl)
ES (1) ES2423484T3 (pl)
PL (1) PL2129373T3 (pl)
WO (1) WO2008119544A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2496233A1 (en) * 2009-11-06 2012-09-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye
WO2016081035A1 (en) * 2014-11-21 2016-05-26 Schoenwetter Phillip E Novel antioxidant formulations
WO2022018605A1 (en) * 2020-07-19 2022-01-27 Narayana Nethralaya Foundation A formulation of combination of genistein and calcitriol for management of inflammatory ocular surface conditions
EP4338798A1 (en) 2022-09-16 2024-03-20 Wasilewicz, Robert Henryk Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US20040197272A1 (en) * 1997-10-16 2004-10-07 Children's Hospital Oakland Compositions and methods for therapy for diseases characterized by defective chloride transport
US20040220116A1 (en) * 2002-06-29 2004-11-04 Dariush Behnam Isoflavone concentrates as well as methods for their production
US7635692B2 (en) * 2001-03-15 2009-12-22 Dsm Ip Assets B.V. Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3482558B2 (ja) * 2000-03-13 2003-12-22 有限会社日中医学研究所 発酵大豆から抽出した、ゲニステインを主要原料とする抗ダイオキシン健康食品。
DE10026245A1 (de) * 2000-05-26 2002-01-24 Bayerische Motoren Werke Ag Verfahren zum Datenaustausch zwischen mehreren Teilnehmern
CN1352896A (zh) * 2000-11-08 2002-06-12 程锦雁 从发酵大豆里提取genistein为抗癌和抗二恶英致癌的物质
KR100380865B1 (ko) * 2000-12-06 2003-04-18 한국 한의학 연구원 골다공증 예방 및 치료에 효과를 갖는 괴화 추출물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US20040197272A1 (en) * 1997-10-16 2004-10-07 Children's Hospital Oakland Compositions and methods for therapy for diseases characterized by defective chloride transport
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US7635692B2 (en) * 2001-03-15 2009-12-22 Dsm Ip Assets B.V. Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
US20040220116A1 (en) * 2002-06-29 2004-11-04 Dariush Behnam Isoflavone concentrates as well as methods for their production

Also Published As

Publication number Publication date
JP5327816B2 (ja) 2013-10-30
KR20100016096A (ko) 2010-02-12
JP2010523507A (ja) 2010-07-15
ES2423484T3 (es) 2013-09-20
WO2008119544A1 (en) 2008-10-09
PL2129373T3 (pl) 2013-10-31
KR101472609B1 (ko) 2014-12-15
EP2129373B1 (en) 2013-05-22
US20180133193A1 (en) 2018-05-17
EP2129373A1 (en) 2009-12-09
CN101652135B (zh) 2012-09-26
US10471041B2 (en) 2019-11-12
CN101652135A (zh) 2010-02-17

Similar Documents

Publication Publication Date Title
US11219590B2 (en) Anti-aging agent and anti-aging method
US10471041B2 (en) Use of geninstein
WO2004066988A1 (ja) 疲労改善剤
CN112512543B (zh) 用于预防、改善或治疗肌肉疾病或用于改善肌肉功能的包含海菊提取物的组合物
JP2019520319A (ja) 小豆を含む筋機能改善又は運動遂行能力向上用組成物
US20200261526A1 (en) Composition For Remedying Female Climacteric Syndrome Symptoms
JP6944221B2 (ja) Ｃｈｐ（シクロ−ヒスプロ）を含む骨損失疾患の予防、改善または治療用組成物
US9084785B2 (en) Composition for accelerating change in muscle type
WO2009136587A1 (ja) 抗疲労組成物
US20190216707A1 (en) Composition for preventing hair loss and promoting hair growth, comprising phytoestrogen as an active ingredient
JP4873904B2 (ja) 眼血管血流障害改善剤
US20070298136A1 (en) Cholesterol regulating agent
WO2006137441A1 (ja) 抗疲労組成物
KR20200140749A (ko) 꾸지뽕나무를 유효성분으로 함유하는 근육 질환 개선, 치료 또는 예방용, 또는 근 기능 개선용 조성물
US20190183811A1 (en) Composition containing squalene for improving muscle function and preventing muscle damage
CN111867575A (zh) 用于改善认知功能的组合物、用于改善焦虑样症状的组合物和用于抑制脑萎缩的组合物
KR102352636B1 (ko) 팔각회향 추출물 또는 시킴산을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
US20220088106A1 (en) Composition comprising cudrania tricuspidate as effective component for alleviating, treating, or preventing muscular diseases, or improving muscule functions
EP2709643B1 (en) Compositions comprising extracts or materials derived from palm oil vegetation liguor for inhibition of vision loss due to macular degeneration
KR20210157502A (ko) 배초향 추출물 또는 틸리아닌를 유효성분으로 함유하는 근육 질환 개선, 치료 또는 예방용, 또는 근 기능 개선용 조성물
US11517603B2 (en) Bone remodeling accelerator
KR20240029547A (ko) 퀸산을 유효성분으로 함유하는 근육 질환 개선, 치료 또는 예방용, 또는 근 기능 개선용 조성물
KR102034314B1 (ko) 적색 파프리카 추출물 또는 캡산틴을 유효성분으로 포함하는 근육 질환 예방, 개선 또는 치료용 조성물
KR20230121587A (ko) 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 포함하는 지방간 예방 또는 치료용 조성물
KR20240133872A (ko) 호밀 화분을 유효성분으로 함유하는 근육 질환 개선, 치료 또는 예방용, 또는 근 기능 개선용 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: DSM IP ASSESTS B.V.,NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRUDENCE, KEVIN;RIEGGER, CHRISTOPH;SCHALCH, WOLFGANG;SIGNING DATES FROM 20091102 TO 20091116;REEL/FRAME:023782/0703

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION